Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Placebo-Controlled, Randomized, Parallel Group, Dose-Ranging Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure Following Penetrating Keratoplasty With LX201 Implantation in Subjects Who Are at Increased Immunological Risk

NCT00447187 is registered in ClinicalTrials.gov with Lux Biosciences, Inc. as lead sponsor.

NCT NCT00447187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00447187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Placebo-Controlled, Randomized, Parallel Group, Dose-Ranging Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure Following Penetrating Keratoplasty With LX201 Implantation in Subjects Who Are at Increased Immunological Risk
Lead sponsor
Lux Biosciences, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
April 30, 2007
Completion date
November 30, 2010
Enrollment
368 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

cornea transplant, corneal diseases